Advanced

In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia

Lonnerholm, Gudmar; Thorn, Ingrid; Sundstrom, Christer; Frost, Britt-Marie; Abrahamsson, Jonas; Behrendtz, Mikael; Heldrup, Jesper LU ; Jacobsson, Stefan; Li, AiHong and Olofsson, Tor LU , et al. (2009) In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis 33(1). p.46-53
Abstract
Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p < 0.001) and doxorubicin (p = 0.01 7), drugs administered during induction therapy. In patients with t(12;21) (n = 20), in vitro sensitivity to doxorubicin was an independent factor for MRD <0.1% (p = 0.031; R-2 = 0.66). Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29. (C) 2008 Elsevier Ltd. All rights reserved.
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Doxorubicin, Prednisolone, 21), t(12, MRD, In vitro drug resistance, Acute lymphoblastic leukemia, Childhood
in
Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
volume
33
issue
1
pages
46 - 53
publisher
Elsevier
external identifiers
  • wos:000261680400007
  • scopus:55049113568
ISSN
1873-5835
DOI
10.1016/j.leukres.2008.06.012
language
English
LU publication?
yes
id
4799634c-3027-4b5e-bdbf-6d9e16f4142f (old id 1313732)
date added to LUP
2009-03-06 15:05:20
date last changed
2017-01-01 04:27:57
@article{4799634c-3027-4b5e-bdbf-6d9e16f4142f,
  abstract     = {Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p &lt; 0.001) and doxorubicin (p = 0.01 7), drugs administered during induction therapy. In patients with t(12;21) (n = 20), in vitro sensitivity to doxorubicin was an independent factor for MRD &lt;0.1% (p = 0.031; R-2 = 0.66). Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29. (C) 2008 Elsevier Ltd. All rights reserved.},
  author       = {Lonnerholm, Gudmar and Thorn, Ingrid and Sundstrom, Christer and Frost, Britt-Marie and Abrahamsson, Jonas and Behrendtz, Mikael and Heldrup, Jesper and Jacobsson, Stefan and Li, AiHong and Olofsson, Tor and Porwit, Anna and Soderhall, Stefan and Larsson, Rolf and Forestier, Erik},
  issn         = {1873-5835},
  keyword      = {Doxorubicin,Prednisolone,21),t(12,MRD,In vitro drug resistance,Acute lymphoblastic leukemia,Childhood},
  language     = {eng},
  number       = {1},
  pages        = {46--53},
  publisher    = {Elsevier},
  series       = {Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis},
  title        = {In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia},
  url          = {http://dx.doi.org/10.1016/j.leukres.2008.06.012},
  volume       = {33},
  year         = {2009},
}